Neutrogena's Helioplex 360 Targets the Wavelengths Your Sunscreen Ignores
If you apply sunscreen daily, you are protecting your skin from a well-mapped set of wavelengths. But solar radiation does not stop at the edges of the UV spectrum. The stretch of light running from 380 to 430 nanometers, technically in the visible range but energetically close enough to ultraviolet to trigger real skin responses, has been an effective gap in sun protection for decades.
At the American Academy of Dermatology (AAD) Annual Meeting in March 2026, Kenvue, the parent company of Neutrogena, presented clinical research behind Helioplex 360: a technology designed specifically to address that gap.
What “Boundary Region Light” Actually Means
Dermatologists classify sunlight damage primarily through two UV categories. UVB (280-320nm) causes direct DNA damage and sunburn. UVA (320-400nm) penetrates deeper, driving photoaging and melanin activation. These are the targets of SPF and PA ratings, the two numbers most people look at on a sunscreen label.
What sits just past 400nm is classified as visible light, and for that reason has historically been excluded from sun protection formulations. But “visible” does not mean “harmless.” The 380-430nm band, sometimes called high-energy visible light (HEVL) or more commonly blue light, carries enough photon energy to induce reactive oxygen species in skin tissue and stimulate melanogenesis, the biological process that produces skin pigmentation.
The challenge is that standard SPF and broad-spectrum testing does not evaluate protection in this range at all. A product can carry an SPF 100 rating while offering zero defense against boundary region light.
Two Studies, One AAD Stage
Kenvue presented two clinical studies at AAD 2026 that form the evidence base for Helioplex 360.
The first examined how the technology modulates pigmentation response and oxidative biomarkers (measurable indicators of cellular oxidative stress) across the full spectrum of human skin tones, from Fitzpatrick Skin Type (FST) I through VI. The goal was to demonstrate that protection is not confined to any single phototype and that the mechanism holds across biological diversity.
The second study focused specifically on FST 5, a medium-deep brown skin tone, to clinically demonstrate how deep UVA combined with high-energy blue light triggers pigmentation in that population. This matters for a specific reason: the research literature on UV-induced pigmentation has historically skewed toward lighter skin tones. The mechanisms and intensity of response in FST 4-6 individuals have been underrepresented in clinical data, even as people with deeper skin tones tend to experience more persistent post-inflammatory and photo-induced hyperpigmentation.
The Sun Care Behavior Gap
Alongside the clinical data, Kenvue released consumer survey results that frame the broader opportunity. Eight in 10 respondents said they use skincare products to address aging. Only 17% said they prioritize sun care, despite acknowledging they understand its preventive value.
The gap between knowing and doing is familiar in skincare behavior. Sun care requires consistent, anticipatory action with benefits that are invisible in the short term. The payoff is a face at 55 that shows less of what 30 years of UV exposure would otherwise accumulate. That kind of deferred reward is genuinely difficult to act on consistently, and it shows in the data.
Helioplex 360’s commercial viability partly depends on whether closing the 380-430nm gap can be communicated to consumers in a way that makes it feel tangible, not just technical.
Beyond Sunscreen: The AAD Neutrogena Presentation
Kenvue used the AAD platform to introduce two additional product directions alongside Helioplex 360.
The Neutrogena Collagen Bank Vitamin C Serum formulates at 15% vitamin C concentration and positions around a dual-action mechanism: stimulating collagen synthesis while inhibiting existing collagen degradation. Vitamin C is one of the more studied topical antioxidants in dermatology, and 15% sits within the range where peer-reviewed evidence supports visible efficacy. The stability and delivery of vitamin C in topical formulations remain ongoing challenges across the category, and how Neutrogena addresses those will matter as much as the concentration figure.
The Neutrogena Hydro Boost line added clinical data supporting its use in post-procedural skin recovery. After in-office treatments such as laser, chemical peel, or microneedling, the skin barrier is temporarily compromised. Redness and surface texture irregularity are common in the days following. The presented data indicates Hydro Boost supports both redness reduction and texture improvement during that recovery window, positioning the line within the post-aesthetic care category that has expanded significantly alongside the broader procedure boom.
Where the Science Goes Next
The boundary region light concept is not entirely new in photobiology. What is new is a major consumer brand presenting clinical data behind a technology that specifically targets it, at a flagship dermatology meeting, with multi-phototype coverage. That changes the conversation from theoretical risk to actionable protection.
Whether the 380-430nm protection gap becomes a standard expectation on sun care labels, similar to how broad-spectrum coverage evolved from niche claim to baseline expectation, depends on how the evidence continues to build and how regulators and brands formalize the category.
For now, the question worth asking when choosing a sunscreen is not just how high the SPF number goes, but how wide the coverage actually extends.
Q. I already use SPF 50+ broad spectrum. Am I missing the 380-430nm window?
Almost certainly yes. Broad-spectrum labeling in most markets certifies coverage up to approximately 400nm, primarily to verify UVA protection alongside UVB. The 380-430nm boundary region sits at the edge of or beyond that defined range, and standard broad-spectrum testing does not specifically evaluate it. A high SPF does not indicate coverage in this window.
Q. Is boundary region light exposure primarily from the sun, or is indoor blue light a factor too?
Sunlight is the dominant source, with blue light intensity several hundred times higher outdoors than from digital screens or indoor LED fixtures. The boundary region light concern in dermatology refers primarily to solar exposure. Screen-based blue light exposure may contribute to other effects, but its role in skin pigmentation and photodamage is not yet supported by the same depth of clinical evidence as solar UVA and HEVL.
Q. How do I identify a sunscreen that covers 380-430nm?
Look for products that explicitly reference Helioplex 360 technology in the Neutrogena line, or more broadly, for brands that cite HEVL or boundary region light protection in their clinical documentation. This is not yet a standardized label category, so the information tends to live in product marketing materials or published research rather than on the label itself. That transparency gap is part of what will need to evolve as this becomes a more recognized criterion.